Genmab — Maj 2021
-
** JPM forecasts 2021 revenues of 7.50 billion crowns ($1.23 billion) and operating income of 1.86 billion crowns, both towards the upper end of the company's guidance range
** It reiterates an "overweight" rating on the stock
** Out of 27 analysts that cover Genmab, 18 rate the stock "strong buy" or "buy", six rate it "hold" and three rate it "strong sell" or "sell" -
Nordea's kommenterer ligeledes i dag. Ser signifikant nyhedsflow fra pipeline de naeste 6 maaneder
-
Tak kkjoel. Jeg håber at få tid til dem alle.
-
Q&A starter kl. 15.
-
Agree E L
-
He said to Michael Schmidt, Guggenheim, at 2021 Q1 cc: "The expansion cohorts will be over 100 patients for each of the expansion cohorts."... "So hopefully, updates also during this year on how that progresses. And we think that, each of these could potentially be used for potential accelerated filing, if the data would allow that. And we certainly, will have interactions with the regulatory authorities on that."
-
Tak for mange gode spørgsmål fra alle. Som vanligt tillod tidsrammen desværre ikke dem alle.
-
Tak kkjoel...Det var ikke nemt i dag mange spørgsmål om de samme emner.
-
Mon vi skal helt frem til 2025 før Jan gider tale om dividende...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind